Lexeo Therapeutics, Inc. announced regulatory updates for LX2006, its gene therapy candidate for treating Friedreich ataxia (FA) cardiomyopathy, including a pivotal study design intended to support accelerated approval. The company hosted a conference call and webcast to discuss these updates. Lexeo Therapeutics, Inc. is a biotechnology company focused on developing gene therapies for rare diseases.
